Skip to main content Skip to search Skip to main navigation

PANGEA XV: Worldwide Campaign against Falsified and Illegally Imported Medicinal Products

From 23 to 30 June 2022, Interpol conducted its 15th globally coordinated operation PANGEA against the illegal online trade of medicines. From fake COVID-19 tests to doping substances or narcotics, the range of illegal shipments was broad.

This year, 94 countries were involved in the operation. A total of more than 3 million units were seized worldwide, including more than 7,800 illegal and counterfeit medicines and medical products. The found counterfeit medicines were mostly produced in Asian countries with counterfeit erectile stimulants originating in India.

During the week, law enforcement

  • Investigated more than 4,000 web links, mainly from social media platforms and messaging apps
  • Shut down or removed more than 4,000 web links containing adverts for illicit products
  • Inspected nearly 3,000 packages and 280 postal hubs at airports, borders and mail distribution or cargo mail centres
  • Opened more than 600 new investigations and issued more than 200 search warrants

While results are still coming in from countries, enforcement actions have already disrupted the activities of at least 36 organized crime groups.

About 40 % of all products seized were counterfeit or unapproved erectile stimulants. Law enforcement agencies in Australia, Argentina, Malaysia, and the United States also seized more than 317,000 unapproved COVID-19 test kits. The seizures in the US alone have an estimated value of nearly USD 3 million.

If you are interested in more information on the global action please click here.


Source:

Interpol: PANGEA XV

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be Interested in the Following Articles:

What are the quality requirements for pharmaceutical gases?

What are the quality requirements for pharmaceutical gases?

You can view the answer here:
Read more
EMA: Update on the Guideline “Stability Testing for Variations”

EMA: Update on the Guideline “Stability Testing for Variations”

The EMA has updated the guideline on stability testing for variations (Revision 3, applicable from 15 January 2026).
Read more
EU: Proposal for Simplification of Medical Device Rules

EU: Proposal for Simplification of Medical Device Rules

The European Commission has proposed targeted reforms to simplify the Medical Device Regulation (Regulation (EU) 2017/745, MDR) and the In Vitro Diagnostic Regulation (Regulation (EU) 2017/746, IVDR) and to address structural implementation challenges.
Read more
EU: Proposal for a European Biotech Act

EU: Proposal for a European Biotech Act

The European Commission has presented a proposal for a European Biotech Act aimed at strengthening Europe’s biotechnology potential and accelerating the translation of innovation from the laboratory to the market.

Read more
EMA: Concept Paper for the Revision of Annex 3 on Radiopharmaceuticals

EMA: Concept Paper for the Revision of Annex 3 on Radiopharmaceuticals

The EMA has published a concept paper outlining a future revision of Annex 3 (Manufacture of Radiopharmaceuticals) of the EU GMP Guidelines. The paper was developed in collaboration with PIC/S and adopted by the GMDP Inspectors Working Group (IWG) at its November meeting.

Read more
EMA: Q&A on QP Certification Without Physical EU Import

EMA: Q&A on QP Certification Without Physical EU Import

The EMA has published a new Q&A addressing QP certification for batches that are neither manufactured within the EU/EEA nor intended for the EU/EEA market, and that are not physically imported into the EU/EEA.

Read more
Previous
Next